-
Mashup Score: 5
The FDA expanded an indication for the SGLT2 inhibitor dapagliflozin to reduce risk for CV death, HF hospitalization and urgent HF visits for adults with HF across the full range of ejection fraction, according to an industry press release.Dapagliflozin (Farxiga, AstraZeneca) was previously approved in the U.S. for adults with HF with reduced EF.
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 17Farxiga extended in the US to reduce risk of cardiovascular death and hospitalisation for heart failure to a broader range of patients - 1 year(s) ago
FDA approval means patients with heart failure can benefit from Farxiga regardless of left ventricular ejection fraction status AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration (FDA)…
Source: www.astrazeneca.comCategories: Expert Picks, Latest HeadlinesTweet-
FDA approves #Farxiga (#dapagliflozin) to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. https://t.co/PSxsZCkapv
-
-
Mashup Score: 1Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial - 1 year(s) ago
Dapagliflozin reduced the risk of first and total non-elective hospitalisations for any cause in people with type 2 diabetes, regardless of the presence of atherosclerotic cardiovascular disease, including hospitalisations not directly attributed to cardiac, kidney, or metabolic causes. These findings might have implications on health-related quality of life for people with type 2 diabetes and on…
Categories: Endocrinology, Latest HeadlinesTweet-
Effects of #dapagliflozin on #hospitalisations in people with type 2 #diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial https://t.co/4OOalOalfR #T2D
-
-
Mashup Score: 1Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial - 1 year(s) ago
Dapagliflozin reduced the risk of first and total non-elective hospitalisations for any cause in people with type 2 diabetes, regardless of the presence of atherosclerotic cardiovascular disease, including hospitalisations not directly attributed to cardiac, kidney, or metabolic causes. These findings might have implications on health-related quality of life for people with type 2 diabetes and on…
Categories: Endocrinology, Latest HeadlinesTweet-
In the April Issue: Effects of #dapagliflozin on #hospitalisations in people with type 2 #diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial https://t.co/eVRPb5m04B
-
-
Mashup Score: 2Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial - 1 year(s) ago
Dapagliflozin reduced the risk of first and total non-elective hospitalisations for any cause in people with type 2 diabetes, regardless of the presence of atherosclerotic cardiovascular disease, including hospitalisations not directly attributed to cardiac, kidney, or metabolic causes. These findings might have implications on health-related quality of life for people with type 2 diabetes and on…
Categories: Endocrinology, Latest HeadlinesTweet-
Effects of #dapagliflozin on #hospitalisations in people with type 2 #diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial https://t.co/4OOalOalfR #T2D #SGLT2 inhibitors https://t.co/zvuebfno2G
-
-
Mashup Score: 0Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial - 1 year(s) ago
Dapagliflozin reduced the risk of first and total non-elective hospitalisations for any cause in people with type 2 diabetes, regardless of the presence of atherosclerotic cardiovascular disease, including hospitalisations not directly attributed to cardiac, kidney, or metabolic causes. These findings might have implications on health-related quality of life for people with type 2 diabetes and on…
Categories: Endocrinology, Latest HeadlinesTweet-
Effects of #dapagliflozin on #hospitalisations in people with type 2 #diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial https://t.co/4OOalOalfR #T2D
-
-
Mashup Score: 3Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial - 1 year(s) ago
Dapagliflozin reduced the risk of first and total non-elective hospitalisations for any cause in people with type 2 diabetes, regardless of the presence of atherosclerotic cardiovascular disease, including hospitalisations not directly attributed to cardiac, kidney, or metabolic causes. These findings might have implications on health-related quality of life for people with type 2 diabetes and on…
Categories: Endocrinology, Latest HeadlinesTweet-
Effects of #dapagliflozin on #hospitalisations in people with type 2 #diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial https://t.co/4OOalOaT5p #T2D
-
-
Mashup Score: 6Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial - 1 year(s) ago
Dapagliflozin reduced the risk of first and total non-elective hospitalisations for any cause in people with type 2 diabetes, regardless of the presence of atherosclerotic cardiovascular disease, including hospitalisations not directly attributed to cardiac, kidney, or metabolic causes. These findings might have implications on health-related quality of life for people with type 2 diabetes and on…
Categories: Endocrinology, Latest HeadlinesTweet-
In the Current Issue: Effects of #dapagliflozin on #hospitalisations in people with type 2 #diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial https://t.co/4OOalOalfR #T2D
-
-
Mashup Score: 0Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial - 1 year(s) ago
Dapagliflozin reduced the risk of first and total non-elective hospitalisations for any cause in people with type 2 diabetes, regardless of the presence of atherosclerotic cardiovascular disease, including hospitalisations not directly attributed to cardiac, kidney, or metabolic causes. These findings might have implications on health-related quality of life for people with type 2 diabetes and on…
Categories: Endocrinology, Latest HeadlinesTweet-
In the April Issue: Effects of #dapagliflozin on #hospitalisations in people with type 2 #diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial https://t.co/4OOalOalfR #T2D #SGLT2 inhibitors
-
-
Mashup Score: 0
NEW ORLEANS — Treatment with the SGLT2 inhibitor dapagliflozin for 24 weeks favorably reduced pulmonary capillary wedge pressure at rest and during exercise in adults with HF with preserved ejection fraction vs. placebo, data show.Elevated left heart filling pressures at rest and during exercise are a fundamental pathophysiologic feature of HFpEF that drive disability, worsen clinical
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Treatment with the SGLT2 inhibitor #dapagliflozin for 24 weeks favorably reduced pulmonary capillary wedge pressure at rest and during exercise in adults with HFpEF vs. placebo @MayoClinicCV @ACCinTouch #ACC23 #cardiotwitter https://t.co/nVoV7brVW8
-
The FDA expanded an indication for the SGLT2 inhibitor #dapagliflozin to reduce risk for CV death, HF hospitalization and urgent HF visits for adults with HF across the full range of ejection fraction @EndocrineToday @US_FDA #cardiotwitter https://t.co/kW84TX7XD4